CORONA Remedies Limited (CORONA) — Financial Results | 22 July 2026
CORONA Remedies Limited announced its Q1 FY27 earnings conference call scheduled for August 3, 2026 at 11:30 a.m. IST to discuss financial results for the quarter ended June 30, 2026, with management representation including the Managing Director, Joint Managing Director, and CFO.
About CORONA Remedies Limited (CORONA)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
📡 Get AI alerts when CORONA files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track CORONA — Free💡 Ask AI about this filing
📊 More CORONA filings
- 🔴 Financial Results — 3 August 2026 CORONA Remedies Limited announced that the audio recording of its Q1 FY27 earnings conference call f...
- 🟡 Board Meeting — 10 July 2026 CORONA Remedies Limited announced the e-voting results and Scrutinizer Report for its 22nd Annual Ge...
- 🟡 Board Meeting — 9 July 2026 CORONA Remedies held its 22nd Annual General Meeting on July 9, 2026 via video conference, approving...
- share transfer — 6 July 2026 CORONA Remedies Limited received a SEBI-mandated certificate confirming Regulation 74(5) does not ap...
- Announcement — 30 June 2026 CORONA Remedies announced the commercial start of operations at its EU-GMP approved women's hormone ...
🔥 Also filed on 22 July 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when CORONA files new disclosures
Track CORONA filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track CORONA — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research